Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sars-cov-2 save search
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
IMNN | News | $1.14 1.33% 49K
|
Manufacturing
|
| O: -7.01%
H: 31.68%
C: 25.1%
imnn-101 sars-cov-2 virus
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
IMNN | News | $1.14 1.33% 49K
|
Manufacturing
|
| O: 1.73%
H: 5.49%
C: 3.44%
imnn-101 vaccine preclinical
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
VXRT | $0.7789 -7.53% 990K
|
Health Technology
|
| O: 0.83%
H: 4.13%
C: -3.72%
primate vaccine sars-cov-2 publication preclinical
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Published: 2024-01-24 (Crawled : 14:30) - globenewswire.com
CAPR | $5.07 0.4% 170K
|
Health Technology
|
| O: 2.18%
H: 6.4%
C: -3.32%
vaccine sars-cov-2 collaboration trial therapeutics
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
Published: 2023-08-24 (Crawled : 15:00) - biospace.com/
IMAB | $1.8 170K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.57%
europe patent international
Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
Published: 2023-05-19 (Crawled : 13:00) - biospace.com/
HOLX | $75.265 0.22% 470K
|
Health Technology
|
| O: 0.54%
H: 1.0%
C: -0.09%
fda clearance
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
Published: 2023-04-17 (Crawled : 18:00) - biospace.com/
GRTS | $0.7241 -2.64% 1.1M
|
Health Technology
|
| O: 1.98%
H: 4.85%
C: -7.77%
antibody mrna sars-cov-2
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
Published: 2023-04-04 (Crawled : 23:00) - globenewswire.com
GRTS | $0.7241 -2.64% 1.1M
|
Health Technology
|
| O: -0.79%
H: 0.8%
C: -0.4%
mrna sars-cov-2
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
Published: 2023-02-13 (Crawled : 02:00) - globenewswire.com
TNXP | $0.159 1.27% 620K
|
Health Technology
|
| O: -3.81%
H: 3.96%
C: 3.96%
pharmaceuticals license potential
American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)
Published: 2023-01-06 (Crawled : 17:00) - biospace.com/
CRYO | $0.0001 0.0% 19K
|
Information
|
| O: 26.98%
H: 0.0%
C: 0.0%
fda trial approval sars-cov-2
Ubiquitome gets FDA authorization with Yale SARS-CoV-2 self-collection tests
Published: 2022-12-19 (Crawled : 14:00) - biospace.com/
PPRUF | News | $358.55 1.5K
|
Consumer Non-Durables
|
| O: -1.67%
H: 1.27%
C: -1.25%
PPRUY | News | $36.0023 220K
|
Manufacturing
|
| O: -0.81%
H: 0.12%
C: -0.83%
fda sars-cov-2 authorization
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.
Published: 2022-12-12 (Crawled : 20:00) - biospace.com/
TNXP | $0.159 1.27% 620K
|
Health Technology
|
| O: 53.52%
H: 32.2%
C: -29.96%
pharmaceuticals license potential
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
Published: 2022-12-06 (Crawled : 18:00) - biospace.com/
SRNE | $0.024 57K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -7.02%
sti-1557 fda clearance trials vaccine mrna virus therapeutics sars-cov-2
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
Published: 2022-12-06 (Crawled : 12:20) - biospace.com/
PFE A | $25.91 2.05% 22M
|
Health Technology
|
| O: -0.13%
H: 0.37%
C: -1.88%
research program sars-cov-2
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
Published: 2022-11-30 (Crawled : 13:00) - biospace.com/
TNXP | $0.159 1.27% 620K
|
Health Technology
|
| O: -0.28%
H: 3.37%
C: 0.0%
pharmaceuticals antiviral antibody presentation platform
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
Published: 2022-11-30 (Crawled : 11:00) - globenewswire.com
DVAX | $11.57 2.03% 1M
|
Health Technology
|
| O: 0.51%
H: 4.02%
C: 3.94%
candidate vaccine sars-cov-2 study
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)
Published: 2022-10-14 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 57K
|
Health Technology
| Email alert
Add to watchlist
sti-9167 preclinical antibody sars-cov-2 publication
Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains
Published: 2022-10-13 (Crawled : 13:00) - prnewswire.com
NVAX | $3.93 1.03% 960K
|
Health Technology
|
| O: -5.01%
H: 13.34%
C: 10.69%
covid-19 candidate antibody vaccine t-cell sars-cov-2 influenza
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
Published: 2022-10-12 (Crawled : 14:00) - biospace.com/
ADTX | $2.38 -1.24% 10K
|
Health Technology
|
| O: 7.12%
H: 4.53%
C: -6.04%
response sars-cov-2 publication infection
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
Published: 2022-10-12 (Crawled : 14:00) - biospace.com/
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: 3.48%
H: 0.0%
C: -4.78%
preclinical vaccine sars-cov-2
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.